Stocks in Focus

Techwing, Inc. Soars 16% on Strong Second-Quarter Results [Stock in the Spotlight]

Shin Ha-yeon
2026-07-14 09:31:24
[E-Daily Reporter Shin Ha-yeon ] Techwing, Inc.(089030)Techwing is surging by over 16% in early trading.
According to MP Doctor on the 14th, as of 9:25 a.m. today, Techwing, Inc. is trading at 50,900 won, up 16.08% from the previous trading day. During the session, the stock rose as high as 51,500 won, a 17.45% increase from the previous close.
Techwing, Inc. announced the previous day that its second-quarter operating profit was preliminarily estimated at 12.505 billion won, a 96.59% increase from the same period last year. Revenue for the same period rose 16.12% to 56.777 billion won.
This rise is also seen as reflecting growing optimism toward semiconductor materials, parts, and equipment (MPE) companies, following SK Group Chairman Choi Tae-won’s recent announcement that he plans to pursue investments worth tens of billions of dollars in U.S. artificial intelligence (AI) and data centers.
Techwing, Inc. is a company specializing in semiconductor testing equipment that develops and manufactures testing equipment for all sectors of the semiconductor industry, supplying products to global semiconductor clients such as SK hynix, SamsungElectronics, Micron, and Intel.

Economy

Corporation

IT·Science

Economy

"Aftermath of the Jensen Huang Scandal… U.S. to Impose Strict Export Controls on China"

“The key point in the Jensen Huang scandal will ultimately be that data centers were built in China and elsewhere, and cloud services were provided to Chinese companies. Given the circumstances, this …
2026-11-13 17:31:12

Corporation

"Baek Jong-won Risk" Eases… The BORN Korea Narrows Third-Quarter Loss

As the controversy surrounding Baek Jong-won, CEO of The BORN Korea, begins to subside, the company’s net loss for the third quarter of this year has narrowed significantly. The quarterly operating lo…
2026-11-13 18:23:44

IT·Science

HANDOK Inc.: Partner Company’s Rare Hypoglycemia Treatment Set to Draw Attention This Year… Results of External Collaboration Put to the Test

Resolute announced to the U.S. Securities and Exchange Commission (SEC) on the 14th (local time) that it had completed patient enrollment for the Phase 3 clinical trial of “Ersodetug.” (Source: U.S. S…
2026-11-13 15:42:02